Pathology and Function of Conduction Tissue in Fabry Disease Cardiomyopathy

Circulation: Arrhythmia and Electrophysiology

Volumn 8, Issue 4, 2015, Pages 799-805

  Frustaci, Andrea ^a   Morgante, Emanuela ^b   Russo, Matteo A ^c   Scopelliti, Fernanda ^b   Grande, Claudia ^b   Verardo, Romina ^a   Franciosa, Pasquale ^a   Chimenti, Cristina ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c IRCCS San RaffaelePisana   (Italy)

Author keywords

arrhythmias; cardiac; cardiomyopathies; electron; Fabry disease; microscopy; mutation

Indexed keywords

ALPHA GALACTOSIDASE; GADOLINIUM;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATRIAL FIBRILLATION; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; ELECTRON MICROSCOPY; FABRY DISEASE CARDIOMYOPATHY; FEMALE; GENE MUTATION; HEART ATRIUM PACING; HEART CATHETERIZATION; HEART ELECTROPHYSIOLOGY; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE BIOPSY; HEART MUSCLE REFRACTORY PERIOD; HEART PREEXCITATION; HEART RIGHT VENTRICLE HYPERTROPHY; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HISTOPATHOLOGY; HOLTER MONITORING; HUMAN; HUMAN TISSUE; HV INTERVAL; HYPERTROPHIC CARDIOMYOPATHY; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PRIORITY JOURNAL; ST SEGMENT; T WAVE; YOUNG ADULT; CARDIOMYOPATHIES; COMPLICATION; ELECTROCARDIOGRAPHY; FABRY DISEASE; HEART ATRIUM; HEART FUNCTION TEST; HEART MUSCLE; HEART MUSCLE CONDUCTION SYSTEM; HEART RATE; HEART VENTRICLE FUNCTION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; RETROSPECTIVE STUDY; ULTRASTRUCTURE;

CARDIOMYOPATHIES; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; FABRY DISEASE; FEMALE; HEART ATRIA; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS; MALE; MICROSCOPY, ELECTRON; MIDDLE AGED; MYOCARDIUM; RETROSPECTIVE STUDIES; VENTRICULAR FUNCTION;

EID: 84939811174     PISSN: 19413149     EISSN: 19413084     Source Type: Journal    
DOI: 10.1161/CIRCEP.114.002569     Document Type: Article

References (20)

1. Desnick RJ, Ioannou YA, Eng CM. Alpha-Galactosidase A Deficiency. Fabry Disease. The Metabolic and Molecular Bases of Inherited Disease. In: Scriver CR; Beaudet AL; Sly WS; Valle D; Kinzler KE; Vogelstein B, eds. New York: McGraw-Hill; 2001: 3733-3774.
2. MacDermot KD, Holmes A, Miners AH. Natural history of Fabry disease in affected males and obligate carrier females. J Inherit Metab Dis. 2001; 24: 13-14.
3. Kampmann C, Baehner F, Whybra C, Martin C, Wiethoff CM, Ries M, Gal A, Beck M. Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol. 2002; 40: 1668-1674.
4. Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, Yoshida A, Kuriyama M, Hayashibe H, Sakuraba H. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med. 1995; 333: 288-293. doi: 10. 1056/NEJM199508033330504.
5. Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee P, McKenna WJ, Elliott PM. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation. 2002; 105: 1407-1411.
6. Chimenti C, Pieroni M, Morgante E, Antuzzi D, Russo A, Russo MA, Maseri A, Frustaci A. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation. 2004; 110: 1047-1053. doi: 10. 1161/01. CIR. 0000139847. 74101. 03.
7. Shah JS, Hughes DA, Sachdev B, Tome M, Ward D, Lee P, Mehta AB, Elliott PM. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol. 2005; 96: 842-846. doi: 10. 1016/j. amjcard. 2005. 05. 033.
8. Igawa O, Miake J, Hisatome I. Ventricular tachycardias and dilated cardiomyopathy caused by Fabry disease. Pacing Clin Electrophysiol. 2005; 28: 1142-1143. doi: 10. 1111/j. 1540-8159. 2005. 00241. x.
9. Chimenti C, Russo MA, Frustaci A. Atrial biopsy evidence of Fabry disease causing lone atrial fibrillation. Heart. 2010; 96: 1782-1783. doi: 10. 1136/hrt. 2010. 196162.
10. Frustaci A, Chimenti C. Images in cardiovascular medicine. Cryptogenic ventricular arrhythmias and sudden death by Fabry disease: Prominent infiltration of cardiac conduction tissue. Circulation. 2007; 116: e350-e351. doi: 10. 1161/CIRCULATIONAHA. 107. 723387.
11. Liang X, Evans SM, Sun Y. Insights into cardiac conduction system formation provided by HCN4 expression. Trends Cardiovasc Med. 2015; 25: 1-9. doi: 10. 1016/j. Tcm. 2014. 08. 009.
12. Chimenti C, Frustaci A. Contribution and risks of left ventricular endomyocardial biopsy in patients with cardiomyopathies: A retrospective study over a 28-year period. Circulation. 2013; 128: 1531-1541. doi: 10. 1161/CIRCULATIONAHA. 13. 001414.
13. Korkotian E, Schwarz A, Pelled D, Schwarzmann G, Segal M, Futerman AH. Elevation of intracellular glucosylceramide levels results in an increase in endoplasmic reticulum density and in functional calcium stores in cultured neurons. J Biol Chem. 1999; 274: 21673-21678.
14. Roudebush CP, Foerster JM, Bing OH. The abbreviated PR interval of Fabry's disease. N Engl J Med. 1973; 289: 357-358. doi: 10. 1056/ NEJM197308162890709.
15. Mehta J, Tuna N, Moller JH, Desnick RJ. Electrocardiographic and vectorcardiographic abnormalities in Fabry's disease. Am Heart J. 1977; 93: 699-705.
16. Namdar M, Kampmann C, Steffel J, Walder D, Holzmeister J, Lüscher TF, Jenni R, Duru F. PQ interval in patients with Fabry disease. Am J Cardiol. 2010; 105: 753-756. doi: 10. 1016/j. amjcard. 2009. 10. 056.
17. Chimenti C, Hamdani N, Boontje NM, DeCobelli F, Esposito A, Bronzwaer JG, Stienen GJ, Russo MA, Paulus WJ, Frustaci A, van der Velden J. Myofilament degradation and dysfunction of human cardiomyocytes in Fabry disease. Am J Pathol. 2008; 172: 1482-1490. doi: 10. 2353/ ajpath. 2008. 070576.
18. Waldek S. PR interval and the response to enzyme-replacement therapy for Fabry's disease. N Engl J Med. 2003; 348: 1186-1187. doi: 10. 1056/ NEJM200303203481224.
19. Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, Kim L, Gass A, Winston J, Dikman S, Fallon JT, Brodie S, Stacy CB, Mehta D, Parsons R, Norton K, O'Callaghan M, Desnick RJ. A phase . clinical trial of enzyme replacement in fabry disease: Pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet. 2001; 68: 711-722. doi: 10. 1086/318809.
20. Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO. Enzyme replacement therapy in Fabry disease: A randomized controlled trial. JAMA. 2001; 285: 2743-2749.